Revelation Biosciences, INC S-1 registration statements

Revelation Biosciences launches a best efforts public offering aiming to raise up to $5 million through shares, pre-funded warrants, and common stock warrants.

Revelation Biosciences files for a best efforts public offering to raise capital for its Gemini-based programs targeting acute kidney injury, chronic kidney disease, and post-surgical infections.

Revelation Biosciences files an amendment to its S-1 registration statement for a proposed public offering of common stock and warrants.

Revelation Biosciences plans a best efforts public offering of common stock, pre-funded warrants, and Class D Common Stock Warrants to raise capital for clinical development and general corporate purposes.